Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- DexCom reported FY 2025 revenue of nearly $4.7 billion, a 15.6% increase, with net income of approximately $836.3 million and a net margin of 17.9%. - Insulet generated FY 2025 revenue of just over $2.7 billion, representing 30.9% growth, with net income of approximately $354.4 million and a net margin near 10.4%. - Both companies face competitive pressures from Abbott, Medtronic, and the rising popularity of GLP-1 drugs, while DexCom is also navigating a March 2025 FDA warning letter. - Insulet is favored for 2026 based on lower price-to-earnings and price-to-sales ratios, plus significant market upside with only 40-45% of type 1 and 5% of type 2 diabetes patients using automated treatment devices.
- The global connected drug delivery devices market is projected to grow from $5.3 billion in 2026 to $12.7 billion by 2035, representing a compound annual growth rate of 10.2%. - Rising chronic disease prevalence including diabetes, asthma, and COPD is driving demand for connected devices that enable precise dosing and long-term therapy management. - Bluetooth-enabled smart wearable injectors currently dominate the market, with over 80 manufacturers offering various connected drug delivery solutions primarily for parenteral administration. - North America leads the market share while Asia-Pacific is expected to experience the highest growth rate through 2035, driven by biopharmaceutical startups and increased device approvals.
- Tandem Diabetes Care received FDA clearance for the Android version of its Mobi insulin pump mobile app, expanding access to the world's smallest automated insulin delivery system. - The approval triggered a nearly 20% surge in TNDM stock to $16.37, reflecting strong investor confidence in the company's technological advancement. - The Android app will enable diabetes patients using Android smartphones to manage their condition through Control-IQ+ technology, which delivers 79% time in range and 90% overnight time in range. - Limited release is expected to begin in December 2025, with commercial availability in early 2026 on Google Play Store for compatible devices including Google Pixel and Samsung Galaxy models.
- Senseonics Holdings signed a memorandum of understanding with Ascensia Diabetes Care to assume global commercialization and distribution of Eversense 365, the world's first year-long continuous glucose monitor, beginning January 1, 2026. - The transition aims to accelerate growth through dedicated commercial infrastructure and eliminate revenue sharing, with Senseonics projecting gross margin expansion to 50% in 2026 and over 70% at scale. - Brian Hansen, current President of CGM at Ascensia and former Chief Commercial Officer at Tandem Diabetes Care, will join Senseonics as Chief Commercial Officer to lead the transition. - The company secured an expanded $100 million non-dilutive debt facility with Hercules Capital to fund the commercial organization and expects 2025 revenue of $34-38 million with approximately doubling of the global patient base.
- The FDA has issued an urgent medical device correction for Tandem Diabetes Care's t:slim X2 insulin pump due to a Malfunction 16 error that stops insulin delivery and could lead to dangerous hyperglycemia. - As of August 12, there have been 700 confirmed adverse events and 59 reported injuries related to the device error, though no deaths have been reported. - Tandem Diabetes Care is developing a software update to enhance early detection of speaker failures and introduce persistent vibration alerts to reduce safety risks. - Users experiencing the malfunction should silence the alarm, switch to backup insulin delivery methods, and contact the company for a replacement device.
- Tandem Diabetes Care will pay Roche $36 million over five years to resolve patent infringement claims related to Tandem's t:slim X2 insulin pump. - The settlement includes mutual licensing agreements for insulin delivery system patents, allowing both companies to continue their operations without further legal disputes for the next decade. - Roche had filed legal action in December 2023 seeking monetary damages and an injunction to halt sales of Tandem's t:slim X2 pump, claiming patent infringement.
- The global diabetes care market is expected to grow from $34.51 billion in 2025 to $62.73 billion by 2032, representing a compound annual growth rate of 8.9%. - Rising diabetes prevalence, with 589 million adults currently living with diabetes globally and projections reaching 853 million by 2045, is driving market expansion. - Continuous glucose monitoring devices and AI-powered diabetes management tools are gaining significant traction, with companies like Abbott and Medtronic partnering to develop integrated automated insulin delivery systems. - Type 2 diabetes accounts for nearly two-thirds of the global diabetes care market share, while North America maintains market dominance with $14.87 billion in revenue expected for 2025.
- Medtronic has submitted 510(k) applications to the FDA for its MiniMed 780G pump as an alternate controller enabled device and its SmartGuard algorithm as an interoperable automated glycemic controller. - The regulatory submissions mark a significant milestone in Medtronic's collaboration with Abbott, which will supply a continuous glucose monitoring sensor based on its most advanced CGM platform. - If cleared, the interoperable system would represent a strategic shift for Medtronic, which previously focused on pairing only its own devices, now offering patients more device integration options.
- Two major clinical trials demonstrate that hybrid closed-loop insulin delivery systems significantly improve time in range and reduce hypoglycemia in pregnant women with type 1 diabetes compared to standard care. - The CRISTAL trial found the MiniMed 780G system reduced time below range by nearly half and improved overnight glycemic control, while also showing potential cost-effectiveness through reduced hospitalizations. - A separate multicenter trial using Control-IQ Technology showed even more dramatic results, with 12.6 percentage points greater time in range and 11.2 mg/dL lower mean glucose levels. - Both studies suggest hybrid closed-loop therapy provides critical safety benefits during pregnancy, with reduced severe hypoglycemia hospitalizations and improved treatment satisfaction for mothers.
- Dexcom's new 15-day continuous glucose monitor demonstrates 8% mean absolute relative difference, positioning it as the most accurate CGM on the market while awaiting FDA clearance expected in the second half of 2023. - Tandem Diabetes Care's Control-IQ+ algorithm for Type 2 diabetes showed significant clinical benefits in a pivotal trial, with patients experiencing a 0.9% reduction in A1C and 16% improvement in time spent in target blood sugar range. - Healthcare provider survey across six countries revealed strong support for CGM as standard care for Type 2 diabetes patients, with 96% of providers endorsing CGM use for those taking multiple daily insulin injections.
